Main Article Content
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our edition uses the copyright terms of Creative Commons for open access journals.
Authors, who are published in this journal, agree with the following terms:
- The authors retain rights for authorship of their article and grant to the edition the right of first publication of the article on a Creative Commons Attribution 4.0 International License, which allows others to freely distribute the published article, with the obligatory reference to the authors of original works and original publication in this journal.
- Directing the article for the publication to the editorial board (publisher), the author agrees with transmitting of rights for the protection and using the article, including parts of the article, which are protected by the copyrights, such as the author’s photo, pictures, charts, tables, etc., including the reproduction in the media and the Internet; for distributing; for the translation of the manuscript in all languages; for export and import of the publications copies of the writers’ article to spread, bringing to the general information.
- The rights mentioned above authors transfer to the edition (publisher) for the unlimited period of validity and on the territory of all countries of the world.
- The authors guarantee that they have exclusive rights for using of the article, which they have sent to the edition (publisher). The edition (the publisher) is not responsible for the violation of given guarantees by the authors to the third parties.
- The authors have the right to conclude separate supplement agreements that relate to non-exclusive distribution of their article in the form in which it had been published in the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.
- The policy of the journal permits and encourages the publication of the article in the Internet (in institutional repository or on a personal website) by the authors, because it contributes to productive scientific discussion and a positive effect on efficiency and dynamics of the citation of the article.
Tsai HY, Ho CT, Chen YK. Biological actions and molecular effects оf resveratrol, pterostilbene, and 3'-hydroxypterostilbene. J Food Drug Anal. 2017 Jan;25(1):134-147. doi: 10.1016/j.jfda.2016.07.004.
Latruffe N, Lançon A, Frazzi R, et al. Exploring new ways of regulation by resveratrol involving miRNAs, with emphasis on inflammation. Ann N Y Acad Sci. 2015 Aug;1348(1):97-106. doi: 10.1111/nyas.12819.
Zhu X, Wu C, Qiu S, Yuan X, Li L. Effects of resveratrol on glucose control and insulin sensitivity in subjects with type 2 diabetes: systematic review and meta-analysis. Nutr Metab (Lond). 2017 Sep 22;14:60. doi: 10.1186/s12986-017-0217-z.
Sokolova LK, Pushkarev VM, Pushkarev VV, Kovzun OI, Tronko MD. Diabetes mellitus and atherosclerosis: the role of inflammatory processes in pathogenesis (literature review). Mìžnarodnij endokrinologìčnij žurnal. 2017;13(7):486-498. doi: 10.22141/2224-07184.108.40.2067.115747. (in Ukrainian).
Sokolova LK, Pushkarev VM, Pushkarev VV, Tronko MD. Mechanisms of pathogenesis of atherosclerosis in patients with diabetes: the role of NF-кB. Problemy endokrynnoyi patologii. 2017;(60):64-76. doi: 10.21856/j-PEP. 2017.2.10. (in Russian).
Berrougui H, Grenier G, Loued S, Drouin G, Khalil A. A new insight into resveratrol as an atheroprotective compound: Inhibition of lipid peroxidation and enhancement of cholesterol efﬂux. Atherosclerosis. 2009 Dec;207(2):420-7. doi: 10.1016/j.atherosclerosis.2009.05.017.
Lin YC, Chen LH, Varadharajan T, et al. Resveratrol inhibits glucose-induced migration of vascular smooth muscle cells mediated by focal adhesion kinase. Mol Nutr Food Res. 2014 Jul;58(7):1389-401. doi: 10.1002/mnfr.201300698.
Deng YH, Alex D, Huang HQ, et al. Inhibition of TNF-α-mediated endothelial cell-monocyte cell adhesion and adhesion molecules expression by the resveratrol derivative, trans-3,5,4 1 –trimethoxystilbene. Phytother Res. 2011 Mar;25(3):451-7. doi: 10.1002/ptr.3279.
Park DW, Baek K, Kim JR, et al. Resveratrol inhibits foam cell formation via NADPH oxidase 1- mediated reactive oxygen species and monocyte chemotactic protein-1. Exp Mol Med. 2009 Mar 31;41(3):171-9. doi: 10.3858/emm.2009.41.3.020.
Rivera L, Morón R, Zarzuelo A, Galisteo M. Long-term resveratrol administration reduces metabolic disturbances and lowers blood pressure in obese Zucker rats. Biochem Pharmacol. 2009 Mar 15;77(6):1053-63. doi: 10.1016/j.bcp.2008.11.027.
Dolinsky VW, Chakrabarti S, Pereira TJ, et al. Resveratrol prevents hypertension and cardiac hypertrophy in hypertensive rats and mice. Biochim Biophys Acta. 2013 Oct;1832(10):1723-33. doi: 10.1016/j.bbadis.2013.05.018.
Gordish KL, Beierwaltes WH. Resveratrol induces acute endothelium-dependent renal vasodilation mediated through nitric oxide and reactive oxygen species scavenging. Am J Physiol Renal Physiol. 2014 Mar 1;306(5):F542-50. doi: 10.1152/ajprenal.00437.2013.
Chang CC, Lin KY, Peng KY, Day YJ, Hung LM. Resveratrol exerts anti-obesity effects in high-fat diet obese mice and displays differential dosage effects on cytotoxicity, differentiation, and lipolysis in 3T3-L1 cells. Endocr J. 2016;63(2):169-78. doi: 10.1507/endocrj.EJ15-0545.
Kim S, Jin Y, Choi Y, Park T. Resveratrol exerts anti-obesity effects via mechanisms involving down-regulation of adipogenic and inﬂammatory processes in mice. Biochem Pharmacol. 2011 Jun 1;81(11):1343-51. doi: 10.1016/j.bcp.2011.03.012.
Vingtdeux V, Giliberto L, Zhao H, et al. AMP-activated protein kinase signaling activation by resveratrol modulates amyloid-beta peptide metabolism. J Biol Chem. 2010 Mar 19;285(12):9100-13. doi: 10.1074/jbc.M109.060061.
Liu T, Bitan G. Modulating self-assembly of amyloidogenic proteins as a therapeutic approach for neurodegenerative diseases: strategies and mechanisms. ChemMedChem. 2012 Mar 5;7(3):359-74. doi: 10.1002/cmdc.201100585.
Weinstein G, Beiser AS, Choi SH, et al. Serum brain-derived neurotrophic factor and the risk for dementia: the Framingham Heart Study. JAMA Neurol. 2014 Jan;71(1):55-61. doi: 10.1001/jamaneurol.2013.4781.
Ye J, Liu Z, Wei J, et al. Protective effect of SIRT1 on toxicity of microglial-derived factors induced by LPS to PC12 cells via the p53-caspase-3-dependent apoptotic pathway. Neurosci Lett. 2013 Oct 11;553:72-7. doi: 10.1016/j.neulet.2013.08.020.
Wong RH, Nealon RS, Scholey A, Howe PR. Low dose resveratrol improves cerebrovascular function in type 2 diabetes mellitus. Nutr Metab Cardiovasc Dis. 2016 May;26(5):393-9. doi: 10.1016/j.numecd.2016.03.003.
He Q, Li Z, Wang Y, Hou Y, Li L, Zhao J. Resveratrol alleviates cerebral ischemia/reperfusion injury in rats by inhibiting NLRP3 inﬂammasome activation through Sirt1-dependent autophagy induction. Int Immunopharmacol. 2017 Sep;50:208-215. doi: 10.1016/j.intimp.2017.06.029.
Abdel-Aleem GA, Khaleel EF, Mostafa DG, Elberier LK. Neuroprotective effect of resveratrol against brain ischemia reperfusion injury in rats entails reduction of DJ-1 protein expression and activation of PI3K/Akt/GSK3b survival pathway. Arch Physiol Biochem. 2016 Oct;122(4):200-213. doi: 10.1080/13813455.2016.1182190.
Li Z, Fang F, Wang Y, Wang L. Resveratrol protects CA1 neurons against focal cerebral ischemic reperfusion-induced damage via the ERK-CREB signaling pathway in rats. Pharmacol Biochem Behav. 2016 Jul-Aug;146-147:21-7. doi: 10.1016/j.pbb.2016.04.007.
Singh N, Agrawal M, Dore S. Neuroprotective properties and mechanisms of resveratrol in in vitro and in vivo experimental cerebral stroke models. ACS Chem. ACS Chem Neurosci. 2013 Aug 21;4(8):1151-62. doi: 10.1021/cn400094w.
Witte AV, Kerti L, Margulies DS, Floel A. Effects of resveratrol on memory performance, hippocampal functional connectivity, and glucose metabolism in healthy older adults. J Neurosci. 2014 Jun 4;34(23):7862-70. doi: 10.1523/JNEUROSCI.0385-14.2014.
Jayasena T, Poljak A, Smythe G, Braidy N, Münch G, Sachdev P. The role of polyphenols in the modulation of sirtuins and other pathways involved in Alzheimer’s disease. Ageing Res Rev. 2013 Sep;12(4):867-83. doi: 10.1016/j.arr.2013.06.003.
Scarlatti F, Maffei R, Beau I, Codogno P, Ghidoni R. Role of non-canonical Beclin 1-independent autophagy in cell death induced by resveratrol in human breast cancer cells. Cell Death Differ. 2008 Aug;15(8):1318-29. doi: 10.1038/cdd.2008.51.
He X, Wang Y, Zhu J, Orloff M, Eng C. Resveratrol enhances the anti-tumor activity of the mTOR inhibitor rapamycin in multiple breast cancer cell lines mainly by suppressing rapamycin-induced AKT signaling. Cancer Lett. 2011 Feb 28;301(2):168-76. doi: 10.1016/j.canlet.2010.11.012.
Selvaraj S, Sun Y, Sukumaran P, Singh BB. Resveratrol activates autophagic cell death in prostate cancer cells via downregulation of STIM1 and the mTOR pathway. Mol Carcinog. 2016 May;55(5):818-31. doi: 10.1002/mc.22324.